NCT01067339View on ClinicalTrials.gov

Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans

PHASE3CompletedINTERVENTIONAL

Enrollment

70

Participants

Timeline

Start Date

February 4, 2010

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Endothelial Dysfunction

Interventions

DRUG

darapladib

darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration

DRUG

placebo

placebo, by mouth, once daily for six months

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Institute on Aging (NIA)

NIH

lead

Mayo Clinic

OTHER